Fundraising FoxSofinnova Ventures — 2015 Investments
6 investments dated 2015 · listed companies and verified rows first · show all
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer.
BiotechDeep TechMedical DevicesCambridge, US
Feng Zhang(Founder)inGeorge Church(Scientific Founder, Professor of Genetics, Harvard University and MIT)inKeith Joung(Scientific Founder, Professor of Pathology, Harvard Medical School)inDavid Liu(Scientific Founder, Professor of Chemistry and Chemical Biology, Harvard University)inKatrine Bosley(Executive Officer, Director)inVic Myer(Executive Officer)in
Co-investorsEcoR1 CapitalGV (Google Ventures)Viking GlobalAtlas VentureDeerfield Management CompanyFlagship Ventures+2 more
eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company.
BiotechSolana Beach, US
Stephen F. Worland, Ph.D.(Executive Officer, Director)Alana McNulty(Executive Officer)in
BoardSimeon George(Director)Jonathan Root(Director)inKen Haas(Director)Laurence Lasky(Director)
Board seatMaha Katabi· per SEC Form D · $56M raise · filed Feb 2016
Co-investorsAstellas Venture Management LLCMission Bay CapitalMission BiocapitalOUP (Osage University Partners)Pfizer Venture InvestmentsUS Venture Partners
The site at this domain is a consumer guide to online casinos in Florida, publishing reviews, rankings, and explanations of gambling laws, bonuses, payment methods, and responsible play.
Media & EntertainmentSan Mateo, US
Anukool Lakhina(Executive Officer, Director)
BoardJose Suarez(Director)Amit Shah(Director)inBrian Wilcove(Director)Andrew Fligel(Director)Michael LaJoie(Director)
Co-investorsQuestMark PartnersTransLink CapitalArtiman VenturesGoldman SachsIntel CapitalSingTel Innov8 Pte Ltd.
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.